About: Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.22 (-0.24%)
TSHA NASDAQ Taysha Gene Therapies Inc
Taysha Gene Therapies Inc share price
Atividade de preço de TSHA
Último preço
$ 4,220
Variação (24h)
-0,01 USD (0,24%)
Volume
2.05M
Volume (média 4 sem.)
-
Abertura
$ 4,23
Variação do dia
$ 4,14 - $ 4,47
Fechamento anterior
$ 4,23
Último negócio
29 Oct, 8:04 pm GMT+0
Atrasado
29 Oct, 8:04 pm GMT+0
TSHA price performance
Atrasado
29 Oct, 8:04 pm GMT+0
quote.marketSignals